# Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

> **NCT05071716** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bausch Health Americas, Inc.** · enrollment: 524 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin SSD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05071716
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-07
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071716, "Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05071716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*